References
- Williams J, Taylor E. The evolution of hyperactivity, impulsivity and cognitive diversity. J Royal Soc Interface. 2006;3:399–413.
- Davidovitch M, Koren G, Fund N, et al. Challenges in defining the rates of ADHD diagnosis and treatment: trends over the last decade. BMC Pediatr. 2017;17:218.
- Bramble D. The use of psychotropic medications in children: a British view. J Child Psychol Psychiatry. 2003;44(2):169–179.
- National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline(NG87); 2018. [cited 2019 Mar]. Available from: https://www.nice.org.uk/guidance/ng87
- Thapar A, Holmes J, Poulton K, et al. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry. 1999;174:105–111.
- Venter A. Adult ADHD. Specialist Forum. 2015;15:42–45.
- Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163:1720–1729.
- Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45(2):150–155.
- Klein RG, Mannuzza S, Olazagasti MAR, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69:1295–1303.
- Du Plessis AME. Attention-deficit/hyperactivity disorder. South Afr Family Pract. 2015;57:24–28.
- Moriyama TS, Cho AJM, Verin RE, et al. Attention deficit hyperactivity disorder, IACAPAP textbook of child and adolescent mental health, Chapter D.1 in externalizing disorders; 2012. p. 1–23.
- Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased cost for patients and their families. J Acad Child Adolesc Psychiatry. 2003;42(12):1415–1423.
- Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Allocation. 2005;3:5.
- Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatr Serv. 2005;56(12):1593–1599.
- Sikirica V, Pliszka SR, Bette KA, et al. Comparative treatment pattern, resource utilization and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manage Care Pharm. 2012;18(9):676–689.
- Holden SE, Jenkins-Jones S, Poole CD, et al. The prevalence and incidence, resource use and financial cost of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health. 2013;7(34):13.
- Austerman J, Muzina DJ. Turning attention to ADHD- US medication trends for attention deficit hyperactivity disorder. The Express Scripts Lab, an Express Scripts Report; 2014 March, 1–29. [cited 2016 Oct 24]. Available from: http://lab.express-scripts.com/lab/insights/industry-updates/report-turning-attention-to-adhd.
- Ponizovsky AM, Marom E, Fitoussi I. Trends in attention deficit hyperactivity disorder drug consumption, Israel, 2005–2012. Pharmacoepidemiol Drug Saf. 2014;23:534–538.
- Scheffler RM, Hinshaw SP, Modrek S, et al. The global market for ADHD medications. Health Aff. 2007;26(2):450–457.
- Ngoepe K. SA has one of the world’s most expensive private healthcare systems – WHO. Health. 2016 February 17;24. [cited 2018 Sept 08]. Available from: https://www.health24.com/News/Public-Health/sa-has-one-of-the-worlds-most-expensive-private-healthcare-systems-who-20160217
- Emsley R, Flisher AJ, Grobler G, et al. The South African Society of Psychiatrists (SASOP) treatment guidelines for psychiatric disorders. SAJP. 2013;19:134–135.
- Standard treatment guidelines and essential medicines list for South Africa, hospital level paediatrics. 4thed. South Africa: The National Department of Health, Pretoria;2017 p. 363–366. [cited 2018 Jun 10]. Available from: http://www.health.gov.za/index.php/component/phocadownload/category/456-hospital-level-paediatrics
- Poulton AS. Transition in ADHD: attention to lifespan. Australas Psychiatry. 2017;25(2):126–129.
- Schoeman R, Liebenberg R. The South African society of psychiatrists/psychiatry management group management guidelines for adult attention-deficit/hyperactivity disorder. SAJP. 2017;23:a1060.
- Truter I. A review of drug utilization studies and methodologies. JJPS. 2008;1(2):91–103.
- World Health Organisation. WHO IWG for drug statistics methodology, WHO CC for drug statistics methodology, WHO CC for drug utilization research and clinical pharmacological services. Introduction to drug utilization research. Oslo; 2003.
- WHO Collaborating. Centre for drug statistics methodology, guideline for ATC classification and DDD assignment 2017. National Institute of Public Health. [cited 2017 Dec 10]. Available from:https://www.whocc.no/filearchive/publications/2017_guidelines_web.pdf
- World Health Organisation. Cost savings of switching private sector consumption from originator brand medicines to generic equivalents. Health systems financing: the path to universal coverage. World Health Report 2010 background paper, Number 35; 2010 [cited 2018 Nov 29]. Available from: http://www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf
- Rossiter D, editor. South African Medicines Formulary (SAMF). 12th ed. Cape Town: Health and Medical Publishing Group for the South African Medical Association; 2016.
- [cited 2018 Dec 2]. Available from: https://www.poundsterlinglive.com/best-exchange-rates/us-dollar-to-south-african-rand-exchange-rate-on-2016-12-31
- [cited 2018 Dec 2]. Available from: https://www.poundsterlinglive.com/best-exchange-rates/british-pound-to-south-african-rand-exchange-rate-on-2016-10-16
- Munasur-Naidoo AP, Truter I. Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study. Int J Clin Pharm. 2019;41(4):859–863.
- Schoeman R, de Klerk M. Adult attention-deficit hyperactivity disorder: a database analysis of South African private health insurance. SAJP. 2017;23:6.
- Truter I. Prescribing of methylphenidate to children and adolescents in South Africa: a pharmacoepidemiological investigation. S Afr Acad Family practice/primary care. 2009;51(5):413–417.
- Wu EQ, Birnbaum HG, Zhang HF, et al. Healthcare costs of adult treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manage Care Pharm. 2007;13(7):561–569.
- Van der Schans J, Kotsopoulos N, Hoekstra PJ, et al. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. PLoS One. 2015;10(5):e0127237.
- Singh I. Beyond polemics: science and ethics of ADHD. Nat Rev Neurosci. 2008;9:957–964.
- Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434–442.
- Chierrito de Oliveira D, Guerro de Sousa P, Borges dos Reis C, et al. Safety of treatments for ADHD in adults: pairwise and network meta-analyses. J Atten Disord. 2019;23(2):111–120. epub2017.
- Asherson P, Akehurst RJJ, Kooij S, et al. Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord. 2012;16(5):S20–S38.
- Bushe C, Wilson B, Televantou F, et al. Understanding the treatment of attention deficit hyperactivity disorder in newly diagnosed adult patients in general practice: a UK database study. Pragmat Obs Res. 2015;6:1–12.
- Chang Z, Lichtenstein P, D’Onofrio BM, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effects of medication. A population based-study. JAMA Psychiatry. 2014;71:319–325.
- Murray A, Vos T, Lozano R, et al. Disability-adjusted life years (DALYS) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–2223.
- The World Medical Association. 2018. World medical association declaration of Helsinki. [cited 2018 Apr 07]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/